Anesthetic and Life Support Drugs Advisory Committee
January 30 & 31, 2002
Questions to the Committee
Opiate Analgesic Development and Use
January 30, 2002: Morning Session
1. Discuss the target population for various opioid formulations and what factors you consider in making this determination?
Opiate Analgesic Use in Pediatric Patients
January 30, 2002: Afternoon Session
1. The FDA is aware that there are still significant unmet needs in pediatric pain management. In the context of the Agency's new mandate to require studies of drugs in children, discuss these unmet pharmacotherapeutic needs in current pediatric pain management and how they might be met with regard to opioid drug products.
2. Discuss the significance of barriers to opioid analgesic trials in children (ethical, safety, scientific, practical, etc). What strategies might be used to overcome barriers?
Anesthetic and Life Support Drugs Advisory Committee
January 30 & 31, 2002
Questions to the Committee
Prescription Drug Abuse
January 31, 2002
The Agency is aware of the growing problems of abuse, misuse and diversion prescription drugs, including the opioid analgesics, among patients and non-patients.
1. Discuss the adequacy of the available data to determine the prevalence of addiction among patients treated with opioids for chronic pain. What can we currently say about the prevalence?
2. Discuss how addiction in a chronic pain patient on opioid therapy can be accurately assessed in the office setting.
3. Discuss the pros and cons of excluding patients with a prior history of substance abuse from clinical trials.
4. Discuss the methods of monitoring for addiction in the clinical setting that may be extended to the Clinical Trials setting.
5. In the context of increasing awareness of the problems of diversion and addiction to prescription opioids among patients and non-patients, comment on what measures might be appropriate to consider in the development of an overall risk management strategy that could reduce abuse and diversion without restricting access to drugs by patients in need of treatment. Comment on what components should be incorporated into such programs.